Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Canadian alternative investment firm Skyline Wealth 16-02-2023, 23:46

Invitation – Ascom Half-Year Results Conference 2024 22-07-2024, 12:00